Piper Sandler analyst Yasmeen Rahimi lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $25 from $72 by removing the LUNAR-COVID Vaccine Global Profit Share from the model, while keeping an Overweight rating on the shares. At Q4/FY25 earnings, management emphasized strong execution of both ARCT-032 cystic fibrosis and ARCT-810 ornithine transcarbamylase deficiency programs, the firm notes. Piper believes 2026 will be a stock-moving year for Arcturus with strong progression across both CF and OTCD programs.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- Arcturus Therapeutics: Dose Selection and Trial Design Uncertainty Justify Neutral Rating Despite Modestly Higher Target Price
- Validating Arcturus’s mRNA Platform: Early Clinical Proof, Solid Cash, and Asymmetric Upside Support a Buy Rating
- Arcturus Therapeutics price target raised to $8 from $7 at Citi
- Arcturus Therapeutics reports Q4 EPS ($1.03), consensus (76c)
- Options Volatility and Implied Earnings Moves Today, March 03, 2026